Scholar Rock Reports Q4 and Full Year 2025 Financial Results and Business Updates
Key Highlights
-
Apitegromab Biologics License Application (BLA) Resubmission and U.S. Launch:
Scholar Rock plans to resubmit the BLA for apitegromab, its lead candidate for spinal muscular atrophy (SMA), following a successful FDA reinspection of Catalent Indiana (now part of Novo Nordisk). U.S. launch is anticipated in 2026, pending FDA approval. -
Regulatory Progress:
The FDA completed a constructive meeting with Catalent Indiana regarding remediation efforts, with no further corrective actions requested. The EMA review of apitegromab’s Marketing Authorisation Application (MAA) is ongoing, with a decision expected by mid-2026 and a European launch targeted for H2 2026, starting in Germany. -
Significant Financing Secured:
Scholar Rock has secured a new debt facility of up to \$550 million in non-dilutive capital from Blue Owl Capital. This funding will support apitegromab commercialization and pipeline advancement. -
Strong Cash Position:
Cash, cash equivalents, and marketable securities stood at \$367.6 million as of December 31, 2025. -
Pipeline Advancement:
The company continues to progress multiple programs, including a Phase 2 trial of apitegromab in infants/toddlers with SMA, a subcutaneous formulation, and a Phase 2 trial in facioscapulohumeral muscular dystrophy (FSHD) set for mid-2026. SRK-439, another myostatin inhibitor, is in Phase 1 with data expected in H2 2026. -
Conference Call:
Management will host a conference call today at 8:00 a.m. ET to discuss results and recent developments.
Detailed Business and Financial Update
Apitegromab Program and Regulatory Developments
- Apitegromab is the only muscle-targeted therapeutic in SMA to show statistically significant and clinically meaningful benefit in a pivotal Phase 3 trial (SAPPHIRE).
- The FDA and Catalent Indiana meeting (Q1 2026) was positive. Novo Nordisk’s remediation of the facility was discussed and no further corrective actions were required. Scholar Rock intends to resubmit its BLA as soon as the FDA reinspects the site successfully.
- The U.S. commercial team is preparing for apitegromab’s launch, focusing on stakeholder engagement and education, particularly with SMA treatment centers and payers.
- The EMA review is ongoing, with a pivotal MAA decision expected mid-2026. European launch planning is underway, starting with Germany in H2 2026.
- Technology transfer to a second U.S. fill-finish facility is ongoing to ensure supply continuity. Scholar Rock expects to submit a supplemental BLA for this facility later in 2026.
- The Phase 2 OPAL study is enrolling infants and toddlers with SMA under two years, whether post-gene therapy or on ongoing SMN2-targeted therapy.
- Development of a subcutaneous formulation of apitegromab is progressing, with a Phase 1 study completed and further regulatory engagements planned.
Pipeline Expansion
- FSHD Program: The IND is cleared for a Phase 2 FORGE trial in facioscapulohumeral muscular dystrophy, a rare and progressive neuromuscular disease affecting ~30,000 people in the U.S. and Europe. The trial is expected to begin in mid-2026.
- SRK-439 Program: SRK-439, a highly selective myostatin inhibitor, is in a Phase 1 study in healthy volunteers. Topline data are expected in H2 2026.
Corporate and Financial Overview
-
New Debt Facility: Scholar Rock secured up to \$550 million in non-dilutive capital from Blue Owl Capital. Structure:
- \$100 million available at closing (used to retire prior debt)
- \$100 million available in Q1 2026
- Up to \$150 million upon FDA approval of apitegromab
- Option for \$200 million additional facilities upon mutual consent
The facility matures in February 2032.
-
Q4 and FY2025 Financials:
- Q4 net loss: \$91.0 million (vs. \$66.5 million Q4 2024); full-year net loss: \$377.9 million (vs. \$246.3 million FY2024)
- Q4 R&D expense: \$46.9 million; FY R&D: \$208.4 million
- Q4 G&A expense: \$45.0 million; FY G&A: \$176.2 million
- No revenue recorded for Q4 or full year 2025 or 2024
- Cash, cash equivalents, and marketable securities at December 31, 2025: \$367.6 million (reflects \$60.4 million from warrant exercises in Q4 2025)
- Total assets at year-end: \$404.3 million; total liabilities: \$158.8 million; stockholders’ equity: \$245.5 million
Potentially Price-Sensitive Information for Investors
- Regulatory Pathway for Apitegromab: The timeline for BLA resubmission and anticipated 2026 U.S. launch is highly significant. Any delays or positive developments with the FDA reinspection or EMA review could materially impact share price.
- Major Non-Dilutive Financing: The \$550 million debt facility provides substantial runway and reduces near-term dilution risk, supporting commercialization and R&D expansion.
- Pipeline Milestones: Multiple near-term clinical milestones in SMA, FSHD, and SRK-439 could serve as catalysts for share price appreciation or volatility.
- Financial Performance: The company continues to operate without revenue, posting significant losses as it invests in pipeline and commercialization. Its cash position, bolstered by the new debt facility and warrant exercises, will be closely watched as the company approaches key regulatory decisions.
- Manufacturing/Operations: Continued progress at the second fill-finish facility and successful FDA reinspection are critical for product launch and supply continuity.
About Scholar Rock
Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for SMA and other rare neuromuscular diseases. The company is a global leader in myostatin biology, leveraging a proprietary platform to develop monoclonal antibodies that modulate protein growth factors with high selectivity.
Investor and Media Contacts
- Investor Contact: Laura Ekas, Ph.D. – [email protected] – 917-439-0374
- Media Contact: Molly MacLeod, Ph.D. – [email protected] – 802-579-5995
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Forward-looking statements are subject to risks and uncertainties, including but not limited to regulatory approvals, clinical trial outcomes, commercialization risks, and changes in financial condition. Investors should review company filings and consult with their financial advisors before making investment decisions.
